BALCAO · CHEMICALS & ALLIED PRODUCTS · SMALL CAP
Biolargo, Inc. BLGO
16 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$7.8M
▼ 56.3% vs FY2024
EPS · FY25
—
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-235.6%
Net margin · FY25
-195.6%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 7.8M
Revenue, FY2025 · full 16-year series below
Revenue
Net income
The company lost 196 cents on every revenue dollar this year.
Per share
—
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-235.6%
Return on equity, FY2025
ROE
Operating margin-191.3%
Net margin-195.6%
Return on assets-161.4%
Each USD of equity lost 236 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+26.1% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+9.7%
+26.1%
+50.8%
+29.7%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years+56.9%
Change, 10 years—
The share count grew 57% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 8.3M
total assets, end of FY2025
Total assetsUSD 8.3M
EquityUSD 4.0M
CashUSD 3.9M
Gross debtUSD 2.1M
Net debtUSD -1.8M
Current ratio1.01×
The company holds more cash than debt.
History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
·
·
·
−0.0
−0.0
−0.0
−0.0
−0.0
·
−0.0
−0.0
·
Income tax $B
·
0.0
0.0
·
·
·
·
·
·
·
·
·
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
·
·
·
·
−0.03
−0.05
−0.08
−0.09
−0.10
−0.09
−0.06
−0.05
−0.04
−0.08
−0.07
−0.13
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−235.6
−55.4
−79.3
−107.7
−162.0
−1137.8
·
·
·
·
·
·
·
·
·
·
Shares out B
·
·
0.29
0.28
·
·
·
·
·
0.09
·
0.08
0.08
0.07
0.06
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
64 of 64
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed